Illuminating Heavy Metals Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Illuminating Heavy Metals Testing
USP <231> Heavy Metals is transitioning toward the incorporation of modern quantitative technologies, but there is still much to be resolved.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 36-42

Industry discussions are currently trying to address individual metal elements, with appropriate methods and appropriate safety-based limits based on the literature. Comments from the Council of Responsible Nutrition, for example, argue that "irrespective of the methodological approach, the absence of clearly defined criteria against which a given method may be assessed precludes the identification of a suitable method. As yet, USP has not defined these criteria. Therefore, it is impossible to comment on the methodology in a meaningful way" (3).

Adds Schoneker, "Overall, the concept of a flexible approach to a methodology is what industry would like to see. Most of the people I've talked to, tend to agree with this as long as there is a clear mechanism for how it will get handled from a regulatory compliance standpoint. That said, industry would like to see USP just use the four key metals during the initial implementation of this concept so we can learn the appropriate approach that can be easily applied to other metals."

During the rest of 2009, the details related to USP ‹231› will undergo revision and strategies for what industry hopes will be a gradual, realistic implementation plan. "There are two different intentions coming at this task," says Boyajian. "USP in the stimuli article seems to be trying to replace the intention of the chapter, while industry as represented by the project team that I am on is saying there was not much there, so adding four elements is already a significant improvement, a great start, and a huge cost increase from what is there now. But I think it's a good thing that we're even discussing it, and it will help us all in the long run."

References

1. USP Ad Hoc Advisory Panel on Inorganic Impurities and Heavy Metals and USP Staff, "General Chapter on Inorganic Impurities: Heavy Metals," stimuli to the revision process, Pharmacopeial Forum 34 (5), 1345–1348 (Sept.–Oct. 2008).

2. N.L. Lewen, "Revision Approaches to the Heavy Metals General Chapter" presented at the USP Annual Meeting, Kansas City, MO 2008.

3. A. Shao, CRN comment letter, Dec. 15, 2008, http://www.crnusa.org/pdfs/CRNComments_USPStimuliarticle12-15-08.pdf.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here